A wholly owned subsidiary of Eli Lilly and Company
Executive Management Team
Chief Development Officer
Frédérique Brune, PharmD
Frédérique Brune has over 20 years’ experience in the field of innovative drug development. Before joining Mablink, Frédérique was VP for Development CMC and Supply Chain at Innate Pharma, a global clinical-stage oncology-focused biotech company developing therapeutic antibodies that harness the immune system to fight cancer. Before that, she spent 10 years in multiple Development Leadership positions at LFB, where she notably oversaw the successful registration of 2 innovative therapeutics. She eventually became LFB’s Quality Director of Bioproduction. Previously, she was Analytical Manager and Project Leader at Pierre-Fabre.
​
At Mablink she has the responsibility of the scientific and preclinical development teams. Her primary objective is to oversee all the operations necessary to obtain INDs for Mablink’s pipeline ADCs.
​
Frédérique holds a PharmD from Paris-Sud University and an MS in Experimental and Clinical Pharmacology from Pierre & Marie Curie University (now part of Sorbonne University, Paris, France).
Chief Medical Officer
Pejvack Motlagh, MD
Dr. Pejvack Motlagh brings to Mablink a deep medical expertise and a robust drug development experience, including over 12 years dedicated to oncology in the industry. Most recently, Pejvack Motlagh was Head of Immuno-Oncology (IO) at Boehringer Ingelheim, leading the global clinical development teams and overseeing and managing their growing IO portfolio composed of more than 20 assets of various modalities and against multiple targets being developed in diverse solid tumors. Previously, he held global positions of increasing responsibilities at leading oncology companies including GSK, Bristol-Myers Squibb and AstraZeneca.
At Mablink, he is responsible for advancing Mablink's clinical pipeline. He leads the company's efforts in clinical development strategy, clinical operations, patient safety, and medical affairs.
Dr. Pejvack Motlagh holds a medical degree from the University of Paris – Faculty of Medicine Necker Enfants-Malades and a Master’s degrees in Immunology and Molecular Biology.
Chief Financial Officer
Stanislas Sordet
Stanislas Sordet holds an MBA from the Burgundy School of Business (France).
​
He started his career as a Senior Auditor at PwC and then spent 15 years at Sanofi Pasteur MSD, where he ended up as the European Director of Finance & Services.
In 2017, he started his own firm Inflexio and then joined Acting to help startups as an interim or part-time financial director.
​
At Mablink, Stanislas brings his extensive experience in financial and corporate development to developing and piloting the management and financial controls. His recent activities helping innovative startups make him a key advisor to the CEO for fundraising strategy and financial engineering topics.
Human Resources Director
Gaëlle Vansteene
Gaëlle Vansteene graduated with a master's degree in Human Resources Management from Lille University, supplemented by a degree in Sociology. She has over 20 years of experience as a Human Resources Director in French and international environments, including as Europe HR Director for KLM Dutch Airlines and most recently as HR Director at Sanofi Pasteur MSD for European countries and then France.
As a professional coach and HR consultant for the past 6 years, Gaëlle brings with her HR expertise, a strong interest in people and team development and fulfillment, which are key to the growth and performance of Mablink.
Management Team
Chief Scientific Officer
Warren Viricel, PharmD, PhD
Dr. Warren Viricel holds a PharmD and a PhD in Biomedical Engineering, respectively from the University of Lyon (France) and the University of Montreal (Canada).
Upon his return to France in 2016 he founded Lina Therapeutics and developed the proprietary “hydrophilic drug-linker ADC platform”, with the help of Prof. Joseph and Prof. Dumontet, two leading names in the field. The technology was entirely transferred to Mablink in 2018.
​
Warren’s experience in medicinal organic chemistry, bioconjugation, pharmacology and antibody-drug conjugates makes him a vital asset of the company.
Head of Preclinical
Research & Development
Lenka Kyrych Sadilkova, PhD
Dr. Kyrych Sadilkova started her career with academic institutions, working on bioconjugation and recombinant proteins projects and then on PK/PD modeling.
Lenka brings her skills in non-clinical pharmacology and team management that she has gained during her 9 years at SOTIO Biotech a.s., a Czech biotech company focusing on the development of innovative oncology immunotherapies. After several years as a Pharmacology Lead, she was promoted to the position of Director of Pharmacology responsible for non-clinical development of several ADCs, including one already in Phase I.
​
An expert in ADCs with a specific experience in target validation and antibody development, she leads Mablink’s biology laboratory, in close collaboration with the CSO and the CDO, to support the development of Mablink’s ADC candidates.
Lenka holds a PhD in Biochemistry and Molecular Biology and a PhD in Gerontology, both from Charles University (Prague, Czech Republic).
Head of CMC Operations and Clinical Supply
Delphine Bregeon, PhD, PMP®
Delphine Bregeon brings over 15 years’ experience in biotechnology. She previously worked at Innate Pharma, a global clinical-stage oncology-focused biotech company developing therapeutic antibodies that harness the immune system to fight cancer. At Innate, she worked for several years as Scientist and R&D Project Manager developing ADC site-specific conjugation technology before moving to Pharmaceutical Operations where she was in charge of CMC and supply project management on early-stage, late-stage and commercial programs.
​
At Mablink she has the responsibility of the management and coordination of all external CMC activities supporting the development of the PSARlink™ linker platform, and of the multiple drug candidates stemming from it.
​
Delphine holds a PhD in Organic, Mineral and Industrial Chemistry from the University of Caen (France) and a PMP® certification (Project Management Professional).
Chief Business Officer
Edouard Leroy
Edouard Leroy holds a master’s degree in Physiology and Physiopathology from the Sorbonne University of Paris (France). He began his career at Servier in a strategic intelligence team. He then joined a biotech company in the field of antibody development before pursuing his career as a sales manager for several global providers in Life Sciences solutions. Overall, Edouard has built up a professional network including the main players in the pharmaceutical and biotech industries in Europe and North America.
​
He joined Mablink in 2020 to lead the business development and portfolio management activities.
Chief Operating Officer
Valérie Attuil, PhD
Dr Valérie Attuil started her career in academic research, working for 10 years in the fields of virology and immunology. With her solid scientific background, she joined a biotech company, which developed polyclonal and monoclonal antibodies, where she worked for 8 years as a product manager. She liaised between R&D, production and marketing, and was also responsible for developing new products.
In her current position, Valerie is ensuring the seamless execution of the development roadmap, covering the facility and supply management, as well as the IT strategy.
​
Valérie Attuil holds a PhD in Immunology from the Ecole Normale Supérieure de Lyon (France).
Chief Quality Officer
David Doreau
David Doreau holds an engineering degree in Biotechnology from the University of Technology of Compiègne (France). In 2012 he joined a French biotech company developing research-grade antibodies.
Before joining Mablink Bioscience in 2021, he spent 3 years working as a LIMS functional administrator in the Quality Excellence division at Sanofi Pasteur's production site in Marcy l'Etoile (France).
At Mablink he is responsible of the Quality Assurance, including the documentation and qualification management as well as the oversight of subcontracted GMP activities.